Circulating miRNAs are promising non-invasive candidate biomarkers for the early detection of disease, prognosis or treatment selection, since their analysis provides access to the humoral state without the need for sequencing the entire human transcriptome.

As efforts continue towards the transition of miRNA profiling from bench to bedside, this webinar will feature the latest technology in the field, represented by the strong assay design of a cancer miRNA RT-qPCR Panel, covering the most useful targets to monitor disease states for low level starting materials or liquid biopsy applications.